Share: 
Status: 
Active
Rating: 
No votes yet
0

Updates in Severe Asthma (MOC)

Course description

You can earn up to 1.5 AMA PRA Category 1 Credit(s). This activity has also been designated by the ABAI for 1.5 MOC Part II Self-Assessment credits. Cost: $30 $15 for College Members, $45 $25 for non-members.

These presentations will review 1) how basic science research has identified distinct pathophysiological endotypes in severe asthma; 2) the use of biomarkers and other tools to categorize the endotype of a severe asthma patient in the allergy/immunology clinic and indicate how these techniques have the potential to improve the care of patients with severe asthma; and 3) examination of the practical approaches currently qavailable for patients not controlled on Step 4 Therapy and look at the role of biologics that will become available in the future of this patient population.

Release Date: 12/15/2015
Expiration Date: 12/14/2018

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning objectives: 

• Recognize how basic science research has identified distinct pathophysiological endotypes in severe asthma 
• Utilize appropriate biomarkers to categorize the endotype of a severe asthma patient in the allergy/immunology clinic 
• Design a management plan that is individualized to a severe asthma patient's particular phenotype and endotype

Credits
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Attendance
  • 1.50 MOC
Faculty

Gerald B. Lee, MD

Elliot Israel, MD

Stephen P. Peters, MD, PhD

Bradley E. Chipps, MD, FACAAI

Additional information
Disclosure: 

Stephen P. Peters, MD, PhD -- Consultant/Advisor: AstraZeneca, Boehringer Ingelheim, CSL Behring, Gilead, Merck, Novartis, Pfizer, Teva, PPD Development, Quintiles, Theron

Bradley E. Chipps, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Boehringer Ingelheim, Genentech, Merck, Novartis; Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Merck, Novartis; Supported/Contracted Research: Stallergenes

The following have no financial relationships to disclose:

Gerald B. Lee, MD

Elliot Israel, MD

Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Attendance
  • 1.50 MOC
Course opens: 
12/15/2015
Course expires: 
12/14/2018
Cost:
$25.00
Please login or create an account to take this course.

Payment required

You must purchase this course.